Acerus Pharmaceuticals (TSE:ASP) Sets New 12-Month Low at $0.08
Acerus Pharmaceuticals Co. (TSE:ASP)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as C$0.08 and last traded at C$0.08, with a volume of 104200 shares changing hands. The stock had previously closed at C$0.08.
The company has a debt-to-equity ratio of 105.08, a current ratio of 0.74 and a quick ratio of 0.40. The company has a market capitalization of $20.90 million and a PE ratio of -1.09. The firm has a 50-day moving average of C$0.11 and a 200 day moving average of C$0.13.
Acerus Pharmaceuticals (TSE:ASP) last released its quarterly earnings data on Tuesday, August 6th. The company reported C($0.01) EPS for the quarter. The company had revenue of C$1.68 million during the quarter, compared to the consensus estimate of C$3.70 million. Equities analysts expect that Acerus Pharmaceuticals Co. will post -0.03 EPS for the current year.
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.
Featured Article: Understanding each part of a balance sheet
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.